Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that researchers will present new data supporting clinical development of VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor being developed for the treatment of hepatitis C, at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna. CNW Group (http://www.newswire.ca/en/releases/archive/April2006/26/c0809.html)
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Clears Additive Orthopedics’ 3D Printed Lattice Plates
The patient-specific implants will be a component of the company’s integrated surgical planning system it plans to launch later in the year.
Gottlieb Says User Fees Will Pay for Post-Market Surveillance Amid Shutdown
FDA activities that most directly impact safety will continue “to the best of our abilities, subject to the legal and financial limitations of the current circumstances,” Gottlieb said.
